FY2024 EPS Forecast for iTeos Therapeutics Lifted by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities research analysts at Wedbush boosted their FY2024 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($3.26) per share for the year, up from their previous estimate of ($3.53). Wedbush has a "Outperform" rating and a $25.00 price target on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.64) per share. Wedbush also issued estimates for iTeos Therapeutics' Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.56) EPS, FY2026 earnings at ($5.26) EPS, FY2027 earnings at ($4.54) EPS and FY2028 earnings at ($1.26) EPS.

Several other equities research analysts also recently issued reports on ITOS. JPMorgan Chase & Co. dropped their target price on iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $31.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Friday.

iTeos Therapeutics Stock Down 2.7 %

iTeos Therapeutics stock traded down $0.23 during trading on Friday, hitting $8.23. The stock had a trading volume of 1,052,727 shares, compared to its average volume of 442,983. The stock has a market cap of $300.64 million, a price-to-earnings ratio of -2.69 and a beta of 1.39. The stock's 50 day moving average is $10.40 and its two-hundred day moving average is $13.99. iTeos Therapeutics has a 1 year low of $7.99 and a 1 year high of $18.75.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in iTeos Therapeutics in the first quarter valued at $3,337,000. Clearline Capital LP bought a new position in iTeos Therapeutics in the second quarter valued at $2,328,000. Candriam S.C.A. bought a new position in iTeos Therapeutics in the second quarter valued at $7,558,000. Kennedy Capital Management LLC bought a new position in iTeos Therapeutics in the first quarter valued at $1,988,000. Finally, Dimensional Fund Advisors LP increased its stake in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock valued at $13,481,000 after acquiring an additional 117,159 shares during the last quarter. Institutional investors own 97.16% of the company's stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.